Cancer Pain Market Report

Cancer Pain Market Analysis By Drug-Class (Opioids, Non-steroidal anti-inflammatory drugs, Aspirin-like drugs, Paracetamol Treatment-related Immunotherapy, Radiotherapy, Chemotherapy, Hormone therapy) 2014 To 2025

Format: PDF  |  Report ID: GVR4253

Pain in cancer may come from compressing or infiltrating nearby body parts, from treatments and diagnostic procedures or from skin, nerve, and the other changes caused by a hormone imbalance or immune response.

Most chronic pain is caused by the illness and most acute pain is caused by treatment or diagnostic procedures. The radiotherapy and chemotherapy may produce painful conditions that persist long after treatment has ended.

The global market for cancer pain therapeutics is expected to post a healthy market growth rate during the forecast period. Steady growth of this market can be attributed to the launch of new products that specifically treats pain-related to cancer.

The presence of pain depends mainly on the location of the cancer and the stage of the disease. At any given time with malignant cancer smacks pain, and two thirds of those with advanced cancer experience pain of such intensity that it adversely affects their sleep, mood, social relation and activities of daily living.

Cancer Pain Market by Drug-Class: Opioids, Non-steroidal anti-inflammatory drugs, others.

Non-steroidal anti-inflammatory drugs  block the production of prostaglandins by inhibiting the cyclooxygenase enzyme and therefore, reduce the pain at the site of injury. The NSAIDs are drug class that groups together drugs that provide analgesic and antipyretic effects, and in higher doses, anti inflammatory effects.

Aspirin-like drugs: These medications are used for bone pain, and pain caused by inflammation. Some people experience stomach problems such as indigestion and bleeding with this type of medication. Aspirin itself is generally avoided; because it is too hard on the stomach if taken regularly.

Paracetamol is important in cancer pain control. It is usually well-tolerated; doesn’t affect the stomach and won’t thin the blood. It is helpful to reduce fever and relieve bone pain, and is often used along with opioids.

Opioids act on ovoid receptors to produce morphine-like effects. Opoids are used most often to relive pain. Opoids are semi-synthetic and synthetic drugs such as hydrocodone, oxycodone, and fentanyl antagonist’s drugs such as naloxone and endogenous peptides such as the endorphins.

Cancer Pain Market by Treatment:

Immunotherapy, which may produce joint or muscle pain;. Radiotherapy, which can cause skin reactions, enteritis, fibrosis, myelopathy, bone necrosis, neuropathy; Chemotherapy, which is often associated with chemotherapy include peripheral neuropathy, mucositis, joint pain, muscle pain, and abdominal pain due to diarrhea.

Hormone therapy: This sometimes causes pain flares. Targeted Therapies, such as trastuzumab and rituximab can cause muscle, joint or chest pain; Angiogenesis inhibitors, like bevacizumab, known to sometimes cause bone pain; and Surgery, which may produce post-operative pain, post-amputation pain or pelvic floor myalgia.

Cancer Pain Market by Treatment Choice: The location of the pain, The severity of the pain, The type of pain such as sharp, tingling or aching, whether the pain is persistent, or comes and goes, what activities or events make the pain worse, what activities or events make the pain better, current medications, how much current medications ease the pain, the impact the pain has on lifestyle, such as poor quality of sleep or loss of appetite.

Cancer Pain Market by Geographical Regions: North America: U.S., Canada, Europe: France, Germany, Italy, Spain, and the England, APAC: China, India, Japan, Australia, Others, Latin America: Argentina, Brazil, Others.

The Key Players include BioDelivery Science, ProStrakan Group, Teva pharmaceuticals, Daiichi Sankyo, Eli-Lilly, Galena Biopharma, Grunenthal Group, GW Pharmaceuticals, Hospira, Johnson & Johnson, Meda Pharmaceuticals, Orexo, Sanofi, Sorrento Therapeutics, WEX Pharmaceuticals.

Key questions answered by the report
Request for Customization

Choose License Type:

Single User - $4,950
Multi User - $7,950
Enterprise User - $9,950

Special Pricing & Discounts

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA